Low‐dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer

摘要: Secondary lymphoid tissue chemokine (SLC/CCL21), one of the CC chemokines, exerts potent antitumor immunity by co-localizing T cells and dendritic at tumor site is currently tested against human solid tumors. Here, we investigated whether combination recombinant adenovirus encoding murine CCL21 (Ad-mCCL21) with low-dose paclitaxel would improve therapeutic efficacy cancer. Immunocompetent mice bearing B16-F10 melanoma or 4T1 breast carcinoma were treated either Ad-mCCL21, paclitaxel, both agents together. Our results showed that Ad-mCCL21 + more effectively reduced growth tumors as compared treatment alone significantly prolonged survival time tumor-bearing animals. These effects combined therapy linked to altered cytokine network site, enhanced apoptosis cells, decreased formation new vessels in Importantly, elicited a strong immunity, which could be partly abrogated depletion CD4+ CD8+ lymphocytes. Collectively, these preclinical evaluations may provide strategy for should considered testing clinical trials.